Jyseleca growth stalls in Q1 update, guidance to be revised
Galapagos reported its Q1 2023 results with Jyseleca coming in 14% below consensus at EUR 26.7m (Q4 2022: EUR 27.1m) as last year's unfavorable EMA PRAC review is putting pressure on JAK inhibitors. Thus, the company plan to most likely lower its FY guidance of EUR 140-160m in the H1 update. Nevert
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.